Small molecule-based PD-1 pathway blockade for Human cancer therapy: ARIH2 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 1/January/2017, 10.02 pm

Cardiac rejuvenation therapy: 17-β Estradiol (17-βE2) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy and heart failure via up regulation of its target gene, 1/January/2017, 12.32 pm
January 1, 2017
Natural product-derived therapy for tuberculosis: Gingerol, one of the main components of Ginger, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene, 1/January/2017, 10.57 pm
January 1, 2017
Show all

Introduction:What they say:

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based PD-1 pathway blockade for Human cancer therapyARIH2 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity

This suggests that ARIH2, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment antitumor activity of the immune system; & (3) inhibit metastatic cancer progression.

price-100

[easy_payment currency=”USD”]Thus, pharmacological formulations encompassing “ARIH2 activators” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100

Undisclosed information: How ARIH2 suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation

For payment and purchase, you may reach us at info@genomediscovery.org


References

Citation: Boominathan, L., Small molecule-based PD-1 pathway blockade for Human cancer therapy: ARIH2 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 1/January/2017, 10.00 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org


Comments are closed.